Risk for thrombotic events reduced after 35 days of rivaroxaban compared with no extended thromboprophylaxis<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Dec. 30, 2021 (HealthDay News) — For patients at high risk for venous thromboembolism (VTE) discharged after COVID-19 hospitalization, thromboprophylaxis with rivaroxaban is associated with improved clinical outcomes, according to a study published online Dec. 15 in The Lancet<\/em>.<\/p>\n Eduardo Ramacciotti, M.D., from the Science Valley Research Institute in S \u00a3o Paulo, Brazil, and colleagues conducted a multicenter randomized trial involving patients hospitalized with COVID-19 at increased risk for VTE who were randomly assigned to receive 35 days of rivaroxaban 10 mg\/day (160 patients) or no anticoagulation (160 patients) at hospital discharge.<\/p>\n During hospitalization, all patients received thromboprophylaxis with standard doses of heparin. Fifty-two percent of patients were in the intensive care unit while hospitalized. Overall, 62 percent of patients had an International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) VTE score of 2 to 3 and elevated D-dimer levels; 38 percent had a score \u00e2\u0089\u00a54. The researchers found that the primary efficacy outcome (a composite of symptomatic or fatal VTE, asymptomatic VTE, symptomatic arterial thromboembolism, and cardiovascular death at day 35) occurred in 3 percent and 9 percent of patients assigned to rivaroxaban and no anticoagulation, respectively (relative risk, 0.33). Neither group had any major bleeding. Two patients in the rivaroxaban group had allergic reactions.<\/p>\n “The use of extended prophylactic-dose rivaroxaban should be considered at hospital discharge as an attractive strategy to improve clinical outcomes in patients with creatinine clearance of more than 30 mL\/minute who were hospitalized with COVID-19 and an IMPROVE VTE score 2 to 3 plus increased D-dimer levels or an IMPROVE VTE score of 4 or more,” the authors write.<\/p>\n Several study authors disclosed financial ties to pharmaceutical companies, including Bayer, which manufactures rivaroxaban and funded the study.<\/p>\n Abstract\/Full Text<\/a><\/p>\n